Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?

Tom A. T. Marcelissen; Gommert A. Van Koeveringe

doi:10.1016/j.eururo.2018.04.019

Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?

Tom A. T. Marcelissen^*, Gommert A. Van Koeveringe

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	334-335
Number of pages	2
Journal	European Urology
Volume	74
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2018.04.019
Publication status	Published - 1 Sept 2018

Keywords

EFFICACY
TOLERABILITY
COMBINATIONS
MONOTHERAPY
PERSISTENCE
ADHERENCE
SYMPTOMS
SYNERGY
PLACEBO

Access to Document

10.1016/j.eururo.2018.04.019

Cite this

@article{5b13f22294034d94af758e83711f0767,

title = "Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?",

keywords = "EFFICACY, TOLERABILITY, COMBINATIONS, MONOTHERAPY, PERSISTENCE, ADHERENCE, SYMPTOMS, SYNERGY, PLACEBO",

author = "Marcelissen, {Tom A. T.} and {Van Koeveringe}, {Gommert A.}",

year = "2018",

month = sep,

day = "1",

doi = "10.1016/j.eururo.2018.04.019",

language = "English",

volume = "74",

pages = "334--335",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder

T2 - The Final Answer?

AU - Marcelissen, Tom A. T.

AU - Van Koeveringe, Gommert A.

PY - 2018/9/1

Y1 - 2018/9/1

KW - EFFICACY

KW - TOLERABILITY

KW - COMBINATIONS

KW - MONOTHERAPY

KW - PERSISTENCE

KW - ADHERENCE

KW - SYMPTOMS

KW - SYNERGY

KW - PLACEBO

U2 - 10.1016/j.eururo.2018.04.019

DO - 10.1016/j.eururo.2018.04.019

M3 - Editorial

C2 - 29724504

SN - 0302-2838

VL - 74

SP - 334

EP - 335

JO - European Urology

JF - European Urology

IS - 3

ER -